TQB2928 + penpulimab

TQB2928 + penpulimab is an **investigational combination therapy** being evaluated for the treatment of advanced malignant tumors[1][3][5]. **Penpulimab** is a monoclonal antibody that targets programmed cell death-1 (PD-1) to block PD-1-mediated immune evasion by tumors, thereby acting as an immune checkpoint inhibitor[2][6][7]. It is a recombinant humanized IgG1 antibody engineered to abolish Fcγ receptor (FcγR) binding, potentially lowering immune-related adverse events while maintaining antitumor efficacy[2][6]. **TQB2928** is a novel, investigational compound; publicly available data indicate its co-development with penpulimab in oncology, but its independent mechanism of action, target, and molecular type are undetermined from public sources.[1][3][5] The combination is being studied for **advanced malignant tumors**, with ongoing or recently completed early-phase clinical trials to assess safety and efficacy[1][3][5]. Penpulimab has been approved as monotherapy or in combination (with chemotherapy) for recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC)[7], but TQB2928 + penpulimab is an experimental combination[1][3][5].

Other names

TQB2928 injection combined with penpulimabTQB-2928 injection combined with penpulimabTQB 2928 injection combined with penpulimab